Chronic intervillositis of unknown etiology is a rare placental condition that affects pregnancy. It involves inflammation in the spaces where maternal blood bathes the placenta, and doctors often find it after miscarriage or stillbirth. People with this condition may notice few early symptoms of chronic intervillositis of unknown etiology, but pregnancies can show poor fetal growth or decreased movements. The condition can recur in future pregnancies and carries a risk of pregnancy loss, but outcomes vary. Treatment focuses on close monitoring and supportive care in pregnancy, and some clinicians use medications like low‑dose aspirin or anti‑inflammatory therapy based on prior history.
Overview
Chronic intervillositis of unknown etiologySymptoms
Most people have no noticeable symptoms. It’s often found when scans show a baby growing too slowly or movements lessen. Chronic intervillositis of unknown etiology is linked to recurrent miscarriage, stillbirth, and preterm birth.
Outlook and prognosis
Many living with chronic intervillositis of unknown etiology face recurrent pregnancy loss or growth-restricted pregnancies, but close monitoring and tailored treatment plans can improve chances over time. Outcomes vary widely between pregnancies. Early specialist care and continuity across pregnancies matter.
Causes and risk factors
Chronic intervillositis of unknown etiology has no confirmed cause. Findings suggest a maternal immune reaction against the placenta. Risk is highest after a prior affected pregnancy; lifestyle or environmental links remain unproven.
Genetic influences
Genetics plays an uncertain role in Chronic intervillositis of unknown etiology. No single gene explains it, but immune-related genetic variations may raise susceptibility. Family clustering is rare; most cases appear sporadic, suggesting complex, non‑Mendelian influences alongside pregnancy‑specific immune factors.
Diagnosis
Diagnosis of chronic intervillositis of unknown etiology relies on examining the placenta under a microscope after delivery or pregnancy loss. Doctors may also rule out infection and other causes; ultrasound and Doppler signs can raise suspicion during pregnancy.
Treatment and drugs
Treatment for chronic intervillositis of unknown etiology focuses on lowering placental inflammation and supporting a healthy pregnancy. Care may include low‑dose aspirin, heparin or other anticoagulation, corticosteroids, and close fetal growth and placental monitoring. Management is individualized, often coordinated by high‑risk obstetrics and maternal‑fetal medicine.
Symptoms
During pregnancy, there are often no clear warning signs you can feel. There may be no early symptoms of chronic intervillositis of unknown etiology, and changes are usually picked up during routine prenatal checks. Symptoms vary from person to person and can change over time. When something is noticeable, it often relates to the baby’s activity or unexpected bleeding.
Many notice nothing unusual at first. With chronic intervillositis of unknown etiology, there may be no warning signs you can feel, especially early in pregnancy. Changes often show up during checkups or scans.
Kicks and rolls may feel less frequent or less strong, especially during times your baby is usually active. This can happen for many reasons, but a sudden or sustained drop in movement needs urgent assessment. If you notice this, contact your maternity unit or healthcare professional the same day.
Light spotting, bleeding, or cramping can occur, particularly if a miscarriage or early labor is beginning. Heavy bleeding, persistent pain, or passing tissue needs immediate care. Call emergency services if you feel faint or are soaking pads quickly.
You may feel fine, but your belly growth appears slower than expected, or clothes fit looser around the abdomen week to week. Clinicians call this fetal growth restriction, which means the baby is measuring smaller than expected for the stage of pregnancy. An ultrasound or fundal height check usually confirms it.
How people usually first notice Chronic intervillositis of unknown etiology?
People often first notice chronic intervillositis of unknown etiology during pregnancy when routine ultrasounds show the baby is measuring small for gestational age or there’s concern about poor growth. Doctors may also spot unusual findings in the placenta after a prior pregnancy loss, stillbirth, or early neonatal complications, and this history can prompt closer monitoring in a new pregnancy. Because CIUE is confirmed by placental pathology after delivery or loss, many learn about it only after a biopsy explains recurrent growth restriction or miscarriages, which then guides care in future pregnancies.
Types of Chronic intervillositis of unknown etiology
Chronic intervillositis of unknown etiology (CIUE) affects the placenta and can lead to pregnancy complications like slowed fetal growth, low birthweight, and in some pregnancies, loss. People may notice different sets of symptoms depending on their situation. There are no widely accepted genetic subtypes, but clinicians describe patterns based on how much of the placenta is involved and whether it has happened in past pregnancies. Understanding the main types of CIUE that doctors describe can help you recognize how symptoms and risks may differ across pregnancies and why monitoring plans vary.
Focal involvement
Only a small area of the placenta is affected. This may cause mild or no noticeable symptoms during pregnancy, and the baby may grow close to expected size. Ultrasound may still pick up subtle growth lag or reduced fluid.
Diffuse involvement
Large portions of the placenta are inflamed. This often links to significant fetal growth restriction and reduced movements later in pregnancy. Doctors may recommend earlier and more frequent surveillance.
Recurrent CIUE
The condition reappears in a subsequent pregnancy. Risks of repeat growth problems or loss are higher, so plans usually include close monitoring and early attention to warning signs. Not everyone will experience every type.
Early-onset CIUE
Changes appear in the first or early second trimester. This is often tied to more severe outcomes, including marked growth restriction or early pregnancy loss. Types of chronic intervillositis described by timing help guide how closely to watch the pregnancy.
Late-onset CIUE
Signs emerge in the late second or third trimester. People may notice slowed belly growth or fewer kicks, and ultrasounds show the baby measuring small for gestational age. Clinicians often weigh timing of delivery to balance growth with safety.
What genetics can tell you about symptoms
Certain HLA and KIR gene patterns may raise the chance of immune overactivation in the placenta, leading to inflammation, heavy first-trimester bleeding, and recurrent miscarriage. Variants in cytokine genes like TNF and IL-10 can heighten inflammation, worsening placental dysfunction and fetal growth restriction.
Causes and risk factors
The exact cause of chronic intervillositis of unknown etiology is not known.
Many experts think it involves an overactive immune response to the placenta.
Known risk factors for chronic intervillositis of unknown etiology include a prior affected pregnancy, and past placental complications may add risk.
There are no well-proven lifestyle or environmental triggers, and it does not usually run in families.
Researchers are still learning how these pieces fit together.
Environmental and biological risk factors
Chronic intervillositis of unknown etiology (CIUE) is a rare placental inflammation that can recur in future pregnancies. Risk factors lean toward internal immune tendencies, with no single outside trigger proven. Doctors often group risks into internal (biological) and external (environmental).
Having CIUE in a previous pregnancy greatly raises the chance it will happen again. The placenta may mount the same inflammatory response in later pregnancies.
CIUE has been reported more often in people with autoimmune disorders such as lupus or antiphospholipid antibodies. Immune activation can make the placenta more likely to attract inflammatory cells.
Some pregnancies show a heightened maternal immune response against placental cells, a core feature of CIUE. This biology can make the intervillous space prone to ongoing inflammation.
Unlike placental infections, CIUE typically shows no bacteria or viruses on testing. This makes common prenatal infections an unlikely environmental driver.
Genetic risk factors
No single gene explains chronic intervillositis of unknown etiology (CIUE). Current evidence points to immunogenetic factors—differences in immune-related genes between the pregnant person and the baby—that may trigger placental inflammation. Genetic risk factors for chronic intervillositis of unknown etiology are still being defined, and Science continues to uncover how these elements interact.
HLA mismatch: Differences between your genes and the baby’s HLA types can shape how the immune system sees the placenta. Certain combinations may raise the chance of an overactive response in the intervillous space. Evidence is growing but not yet definitive.
KIR–HLA-C pairing: Genes on the pregnant person’s side that control natural killer cell receptors (KIR) interact with the baby’s HLA-C type. Some pairings have been linked to abnormal placental shaping in other conditions and are being studied in CIUE. Findings suggest possible risk patterns, but no single pairing explains all cases.
HLA-G variation: HLA-G helps the placenta signal for immune tolerance. Variants that change its levels or function may influence CIUE risk. Research is ongoing to confirm how strong this effect is.
Complement genes: Genes that regulate the complement system can affect inflammation where maternal blood meets the placenta. Variants in these genes are under investigation for a role in CIUE. Clear links have not been proven.
Thrombophilia variants: Changes such as Factor V Leiden or prothrombin variants are common genetic risks for clotting. Studies in CIUE show mixed, often weak associations. At present, they are not considered a consistent cause.
Inherited immune traits: The high chance of recurrence in the same individual points toward a genetic predisposition in immune regulation. This likely involves several small-effect variants rather than a single gene. Specific inheritance patterns have not been demonstrated.
Autoimmune tendency genes: Genes that raise the chance of autoimmune reactions may also tilt the immune balance in pregnancy. Such variants are plausible contributors to CIUE but have not been confirmed. People with the same risk factor can have very different experiences.
Fetal genetic makeup: Most babies in CIUE-affected pregnancies have typical chromosomes, suggesting fetal genetic disorders are not the main driver. Still, the baby’s HLA type can influence how the maternal immune system responds. No specific fetal gene has been pinpointed.
Lifestyle risk factors
Research on modifiable habits in this condition is sparse, and no lifestyle factor is proven to cause or prevent it. However, everyday behaviors can influence maternal inflammation, vascular health, and placental function, which may affect how CIUE presents or compounds risks during pregnancy. Evidence for lifestyle risk factors for Chronic intervillositis of unknown etiology is limited, so changes should be individualized with your obstetric team. The aim is to avoid added placental stressors and support balanced immune and vascular function.
Nicotine and smoke byproducts impair placental blood flow and increase oxidative stress. Avoiding tobacco and e‑cigarettes removes additional inflammatory burden that could aggravate intervillous inflammation.
Household or workplace smoke exposure can reduce placental oxygen delivery. Minimizing exposure may help reduce additive inflammatory and vascular stress on a placenta vulnerable to CIUE-related lesions.
Alcohol increases oxidative stress and worsens placental function and fetal growth. Abstaining during pregnancy removes a modifiable insult that could compound intervillous inflammation.
Cocaine, methamphetamine, and similar stimulants cause vasoconstriction that compromises placental perfusion. Avoidance may reduce hypoxic and inflammatory triggers that could aggravate CIUE pathology.
Risk prevention
Chronic intervillositis of unknown etiology (CIUE) affects the placenta and can raise the risk of miscarriage, stillbirth, and growth problems in future pregnancies. There are often no early symptoms of chronic intervillositis of unknown etiology, so prevention focuses on planning the next pregnancy and close care from the start. While there is no guaranteed way to prevent CIUE, working with a high-risk pregnancy team can lower complications and may reduce recurrence. Prevention works best when combined with regular check-ups.
Meet with a maternal–fetal medicine specialist to review prior pregnancy records and confirm the diagnosis. Create a plan before conceiving that outlines medications, monitoring, and when to seek care.
Book prenatal care as soon as you have a positive test. Early visits allow timely steps that may lower the chance of recurrence and complications of CIUE.
Your clinician may recommend daily low‑dose aspirin, often 75–150 mg (81 mg in the US), started early in pregnancy. This may support placental blood flow and lower related risks.
In some cases, heparin injections or immune‑modulating medicines (such as hydroxychloroquine or steroids) are considered. These are individualized, and evidence is limited, so they should be used only under specialist guidance.
Transmission
Chronic intervillositis of unknown etiology is an inflammatory condition of the placenta that arises during pregnancy and is not an infection. It cannot be transferred between people or caught from a partner, and it is not sexually transmitted.
There is no genetic transmission of chronic intervillositis of unknown etiology to the baby; it does not mean the baby inherits a disease. The condition can recur in future pregnancies in the same person, likely related to immune factors, but this is recurrence rather than transmission. If you are wondering whether chronic intervillositis of unknown etiology is contagious, the answer is no.
When to test your genes
Consider genetic testing if chronic intervillositis of unknown etiology recurs across pregnancies, especially with early losses, severe fetal growth restriction, or unexplained stillbirth. Testing can clarify immune, thrombophilia, or placental pathway risks and guide tailored prevention in future pregnancies. Discuss timing preconception or early in pregnancy with a maternal–fetal medicine specialist.
Diagnosis
During pregnancy, first clues often show up as slowed fetal growth on ultrasound or reduced movements that bring you in for extra checks. Because there isn’t a single blood test or scan that proves it before delivery, doctors often rely on the placenta after birth to confirm the diagnosis of Chronic intervillositis of unknown etiology. Early and accurate diagnosis can help you plan ahead with confidence. Many people feel relief just knowing what’s really going on.
Your team reviews any prior miscarriages, stillbirths, or severe growth restriction. Patterns across pregnancies can raise suspicion for chronic intervillositis of unknown etiology. This context guides what tests to prioritize now.
Sonographers track your baby’s growth and the placenta’s appearance. They also look for signs of poor blood flow that can go along with this condition. Ultrasound findings suggest risk but cannot confirm CIUE on their own.
Blood-flow measurements in the umbilical and uterine arteries help assess placental function. Abnormal waveforms support concern when growth is lagging. These exams help decide how closely to monitor the pregnancy.
Nonstress tests and biophysical profiles check the baby’s well-being over time. Repeated low scores or concerning trends add weight to the suspicion. From here, the focus shifts to confirming or ruling out possible causes.
Stages of Chronic intervillositis of unknown etiology
Chronic intervillositis of unknown etiology does not have defined progression stages. It’s a placental finding that tends to appear during a pregnancy and may recur in later pregnancies, rather than moving through stepwise stages in the parent; early symptoms of chronic intervillositis of unknown etiology are not specific or usually noticeable. It’s typically confirmed by examining the placenta under a microscope after delivery or a pregnancy loss; during pregnancy, clinicians may only suspect it based on past history, slowed fetal growth, or Doppler ultrasound changes in blood flow. Specialist input may be helpful if the first results are not conclusive.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially after hearing a diagnosis of chronic intervillositis of unknown etiology. This rare placental condition tends to recur in future pregnancies, sometimes in a milder way and sometimes more severely. The outlook is not the same for everyone, but careful planning before conception, close monitoring during pregnancy, and early treatment strategies can improve the chances of a healthy birth.
Understanding the prognosis can guide planning and help set expectations for the next pregnancy. Without targeted care, chronic intervillositis of unknown etiology is linked to higher risks of miscarriage, fetal growth restriction, and stillbirth; fortunately, maternal mortality is not a typical feature. Some centers use combinations of aspirin, blood thinners, immune-modulating medicines, and frequent ultrasounds to lower risks, though results vary and evidence is still evolving.
When thinking about the future, it helps to know that many people maintain good overall health between pregnancies because the condition affects the placenta rather than long-term maternal organs. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, but for chronic intervillositis of unknown etiology, the main drivers seem to be immune and placental factors rather than inherited risk. Early care can make a real difference, especially when teams watch closely for early symptoms of chronic intervillositis of unknown etiology in a new pregnancy—such as slowed fetal growth on scans—and adjust treatment quickly. Talk with your doctor about what your personal outlook might look like, including your chances of recurrence, which medicines might help in your situation, and the monitoring plan that fits your goals.
Long-term effects
Chronic intervillositis of unknown etiology can have lasting effects that mostly show up in later pregnancies and in baby outcomes rather than your day‑to‑day health between pregnancies. Long-term effects vary widely, and they don’t look the same for everyone. There are often no early symptoms of chronic intervillositis of unknown etiology, so issues are usually discovered through pregnancy ultrasound or after birth when the placenta is examined. The long-term picture centers on higher chances of pregnancy complications, the need for closer monitoring, and potential impacts on newborn health if growth or timing of birth is affected.
CIUE can recur, meaning a higher chance of similar placental inflammation in later pregnancies. This raises the overall risk of complications and usually prompts a tailored care plan next time.
People with CIUE have an increased chance of miscarriage or stillbirth in future pregnancies. The level of risk can differ from one pregnancy to the next.
Babies may grow more slowly because the placenta doesn’t transfer enough oxygen and nutrients. This can lead to small‑for‑gestational‑age births and the need for closer growth scans.
CIUE is linked with early delivery, either spontaneous or planned for safety. Preterm birth can bring short‑ and longer‑term challenges for breathing, feeding, and development.
How is it to live with Chronic intervillositis of unknown etiology?
Living with chronic intervillositis of unknown etiology can feel uncertain, especially during pregnancy, because the condition often becomes known only after complications such as slowed fetal growth or prior pregnancy losses. Day to day, many rely on frequent prenatal visits, close ultrasound monitoring, and careful planning with a high‑risk obstetrics team, which can be emotionally taxing but also reassuring. Partners, family, and friends often share the stress and may adjust work, travel, and support plans to help with appointments and rest. For many, having a clear care plan, open communication with clinicians, and support from others who have faced similar pregnancies helps restore a sense of control and hope.
Treatment and drugs
Treatment for chronic intervillositis of unknown etiology (CIUE) focuses on lowering inflammation in the placenta, reducing immune attack, and closely monitoring the pregnancy. Although living with chronic intervillositis of unknown etiology can feel overwhelming, many people manage their symptoms and live fulfilling lives. Doctors sometimes recommend a combination of lifestyle changes and drugs, often using low‑dose aspirin, blood thinners such as heparin, and medicines that calm the immune system like corticosteroids; some specialists may add hydroxychloroquine or other immunomodulators based on prior pregnancy history. Care typically includes more frequent ultrasounds, Doppler blood‑flow checks, and fetal growth monitoring, with plans adjusted if there are signs of poor growth or placental problems. Not every treatment works the same way for every person, so your doctor may adjust your plan over time and discuss options for future pregnancies, including preconception planning and early treatment starts.
Non-drug treatment
Chronic intervillositis of unknown etiology affects how a pregnancy is watched and planned, more than how you feel day to day. There are usually no early symptoms of chronic intervillositis of unknown etiology that you can feel, so monitoring focuses on your baby’s growth and well-being. Alongside medicines, non-drug therapies can support a healthy pregnancy and guide safe timing of delivery. Care is individualized and usually led by a high‑risk pregnancy team.
Meet with a maternal–fetal medicine specialist before trying to conceive. You’ll review prior pregnancies, recurrence risk, and a plan tailored to you. This visit also helps optimize any health conditions before pregnancy.
High-risk clinics coordinate care across obstetrics, genetics, and neonatology. More frequent check-ins help spot changes early. A shared plan can reduce last‑minute decisions.
Regular scans track your baby’s size, placenta appearance, and amniotic fluid. This helps identify growth slowing early. Results guide how often you’re seen and when to deliver.
Ultrasound Doppler looks at blood flow in the cord and placenta. Abnormal patterns can signal stress before symptoms appear. Doctors use this to fine‑tune monitoring and timing.
Your genes may have an impact on how drugs work for you
Medicines used during pregnancy for chronic intervillositis of unknown etiology can work differently based on genetic differences in drug-processing enzymes and immune pathways. These differences may affect effectiveness and side effects, so clinicians sometimes tailor choices and doses accordingly.
Pharmacological treatments
Chronic intervillositis of unknown etiology (CIUE) is rare, so treatment aims to lower inflammation and reduce tiny clots in the placenta to help protect the pregnancy. Because early symptoms of Chronic intervillositis of unknown etiology can be unclear, doctors often start medicines before problems show up, based on past pregnancy history and biopsy results. Care plans usually combine several drugs and close monitoring in pregnancy. Not everyone responds to the same medication in the same way.
Low-dose aspirin helps prevent small placental clots and supports blood flow. It is widely used in pregnancy for placental conditions and is often started early.
Enoxaparin, a low‑molecular‑weight heparin, thins the blood to reduce clotting in the placenta. It may also have gentle anti‑inflammatory effects on the lining of the placenta.
These corticosteroids calm an overactive immune response that can inflame the placenta. Dosing may be increased or lowered gradually to balance benefits and side effects.
Hydroxychloroquine tames immune activity and may lower placental inflammation. It has a long track record in pregnancy for autoimmune conditions and is sometimes added when risk is high.
Genetic influences
For chronic intervillositis of unknown etiology (CIUE), researchers have not found a single inherited cause or a specific gene that explains the condition. It’s natural to ask whether family history plays a role. Most evidence points to a complex interaction between the mother’s immune system and the placenta during pregnancy, which may be influenced by small differences in immune-related genes in the mother and, at times, by the baby’s genetics. CIUE tends to recur for the same pregnant person across pregnancies, but it does not usually run through families across sisters or generations. Because no clear hereditary pattern is known, genetic testing for chronic intervillositis of unknown etiology is not routinely recommended, though a genetics or maternal–fetal medicine specialist may consider it if there are other concerns about the pregnancy. Genetic counseling can help review your history, discuss recurrence risk, and decide whether any tests could add useful information alongside close pregnancy monitoring.
Is Chronic intervillositis of unknown etiology genetic?
Genetics plays an uncertain role in Chronic intervillositis of unknown etiology. No single gene explains it, but immune-related genetic variations may raise susceptibility. Family clustering is rare; most cases appear sporadic, suggesting complex, non‑Mendelian influences alongside pregnancy‑specific immune factors.
Pharmacogenetics—how genetics influence drug effects
While the cause of Chronic intervillositis of unknown etiology (CIUE) isn’t clear, genetics can still matter when choosing and dosing medicines used to calm inflammation or reduce clotting risk during pregnancy. When drugs like tacrolimus or azathioprine are considered in difficult, recurrent cases of CIUE, differences in drug‑processing genes can change how much medicine you need and your risk of side effects. Genetic testing can sometimes identify how your body processes these medicines, helping doctors tailor the dose and monitoring. For commonly used treatments in CIUE—such as low‑dose aspirin, heparin, corticosteroids, or hydroxychloroquine—pharmacogenetic guidance is limited today, so dosing relies more on clinical response, blood tests, and the normal changes pregnancy brings. Response also depends on many non‑genetic factors, including body size, other medications, liver and kidney function, and gestational age. Alongside medical history and close monitoring, ask your specialist whether pharmacogenetic testing could add value to your CIUE treatment plan, especially if stronger immunosuppressants are being used.
Interactions with other conditions
In pregnancies with chronic intervillositis of unknown etiology (CIUE), other placental-related problems such as fetal growth restriction and preeclampsia often occur together, which can compound risks for the baby and the birthing parent. Some conditions share “underlying mechanisms,” such as an overactive immune response to the placenta, which may explain why CIUE has been reported alongside autoimmune illnesses like antiphospholipid syndrome or lupus. Certain infections—including malaria or cytomegalovirus—can cause placental inflammation that looks similar under the microscope, so healthcare teams work to rule these out because treatment and monitoring differ. There are no early symptoms of chronic intervillositis of unknown etiology that you can feel, so overlaps are usually picked up through ultrasound findings like slowed fetal growth or abnormal blood-flow studies, or through tests done for another condition. When CIUE coexists with preeclampsia, high blood pressure and reduced placental blood flow may be more pronounced, raising the likelihood of preterm delivery and the need for closer surveillance.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described pregnancies where the baby stopped growing despite a healthy parent and careful prenatal care. Families and clinicians noticed a pattern: normal early ultrasounds, then slowed growth, reduced fetal movement, and sometimes repeated late losses. Only later did careful study of the placenta reveal a distinctive picture—widespread inflammation in the spaces where maternal blood bathes the placenta—now recognized as chronic intervillositis of unknown etiology (CIUE).
First described in the medical literature as a chronic inflammatory placental lesion in the late 20th century, CIUE was initially pieced together from placental exams after stillbirths or severe growth restriction. Pathologists saw clusters of immune cells filling the intervillous space and deposits that hinted at an immune process, yet no infection or clear cause was found. From these first observations, clinicians began linking the placental pattern to recurring pregnancy complications in the same person, sometimes across several pregnancies.
As medical science evolved, improved placental staining, imaging, and standardized reporting helped define CIUE more clearly and distinguish it from infection, preeclampsia-related changes, or other inflammatory conditions. Researchers explored whether CIUE might be the placenta’s version of a misdirected immune response—somewhat like the body reacting to the placenta as if it were “not self”—but a single trigger never emerged. The “unknown etiology” label reflects that careful testing often rules out infections, autoimmune disorders, and clotting problems, yet the inflammation persists.
With each decade, case series and registries broadened the picture: CIUE can appear in first pregnancies or after uncomplicated births, can recur, and is strongly associated with fetal growth restriction and stillbirth. Awareness expanded from specialized pathology reports to multidisciplinary care teams, so more placentas from complicated pregnancies were examined, and earlier clues were recognized. In recent decades, knowledge has built on a long tradition of observation, and early symptoms of CIUE—like slower fetal growth or decreased movement—are now understood as downstream effects of placental inflammation rather than warning signs without a name.
Genetics and immunology studies have looked for inherited risks or specific immune pathways, but no single gene or biomarker defines CIUE. This has shaped the practical approach: careful monitoring in future pregnancies, individualized use of therapies aimed at calming inflammation or supporting the placenta, and routine placental examination after delivery to confirm the diagnosis. Over time, the way the condition has been understood has changed, but the central lesson remains consistent: studying the placenta after adverse outcomes has been key to recognizing CIUE and guiding care in subsequent pregnancies.